The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid

Research output: Contribution to journalArticleResearchpeer-review

34 Citations (Scopus)

Abstract

BACKGROUND AND AIMS: The life expectancy of patients with cystic fibrosis (CF) has been increasing and the associated liver disease has emerged as a significant medical issue. Our aim was to describe the clinical features, course and effect of ursodeoxycholic acid (UDCA) on liver disease in an adult CF population. STUDY: From 1983 to 2005, 278 patients with CF were followed up at the Alfred Hospital, an adult tertiary referral centre. Twenty-seven patients (9.7 ) satisfied the criteria for liver disease and their clinico-pathological features were assessed. The effect of UDCA on hepatobiliary symptoms and biochemical parameters was determined. RESULTS: The mean age at liver disease diagnosis was 23 years (range 8-47 years). Portal hypertension was present in 18 (67 ) patients. During a median follow-up of 7 years (range 1.5-15), variceal haemorrhage occurred in two patients and ascites in three (one spontaneously). Nine (33 ) patients died and five (19 ) underwent lung transplantation. There was no encephalopathy, liver transplantation or liver-related deaths. UDCA was taken by 22 patients and was associated with a significant improvement in hepatobiliary symptoms [11/22 (50 ) in the pre-UDCA period vs 1/22 (4 ) in the post-UDCA period; P=0.0003] and a significant reduction in aspartate aminotransferase (P=0.005); alanine aminotransferase (P
Original languageEnglish
Pages (from-to)1402 - 1408
Number of pages7
JournalLiver International
Volume27
Issue number10
DOIs
Publication statusPublished - 2007

Cite this

@article{3e5c723242ce477a8d1d3bddab5348df,
title = "The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid",
abstract = "BACKGROUND AND AIMS: The life expectancy of patients with cystic fibrosis (CF) has been increasing and the associated liver disease has emerged as a significant medical issue. Our aim was to describe the clinical features, course and effect of ursodeoxycholic acid (UDCA) on liver disease in an adult CF population. STUDY: From 1983 to 2005, 278 patients with CF were followed up at the Alfred Hospital, an adult tertiary referral centre. Twenty-seven patients (9.7 ) satisfied the criteria for liver disease and their clinico-pathological features were assessed. The effect of UDCA on hepatobiliary symptoms and biochemical parameters was determined. RESULTS: The mean age at liver disease diagnosis was 23 years (range 8-47 years). Portal hypertension was present in 18 (67 ) patients. During a median follow-up of 7 years (range 1.5-15), variceal haemorrhage occurred in two patients and ascites in three (one spontaneously). Nine (33 ) patients died and five (19 ) underwent lung transplantation. There was no encephalopathy, liver transplantation or liver-related deaths. UDCA was taken by 22 patients and was associated with a significant improvement in hepatobiliary symptoms [11/22 (50 ) in the pre-UDCA period vs 1/22 (4 ) in the post-UDCA period; P=0.0003] and a significant reduction in aspartate aminotransferase (P=0.005); alanine aminotransferase (P",
author = "Desmond, {C P} and Wilson, {John W} and Bailey, {Michael John} and Denise Clark and Roberts, {Stuart K}",
year = "2007",
doi = "10.1111/j.1478-3231.2007.01570.x",
language = "English",
volume = "27",
pages = "1402 -- 1408",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "10",

}

The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid. / Desmond, C P; Wilson, John W; Bailey, Michael John; Clark, Denise; Roberts, Stuart K.

In: Liver International, Vol. 27, No. 10, 2007, p. 1402 - 1408.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid

AU - Desmond, C P

AU - Wilson, John W

AU - Bailey, Michael John

AU - Clark, Denise

AU - Roberts, Stuart K

PY - 2007

Y1 - 2007

N2 - BACKGROUND AND AIMS: The life expectancy of patients with cystic fibrosis (CF) has been increasing and the associated liver disease has emerged as a significant medical issue. Our aim was to describe the clinical features, course and effect of ursodeoxycholic acid (UDCA) on liver disease in an adult CF population. STUDY: From 1983 to 2005, 278 patients with CF were followed up at the Alfred Hospital, an adult tertiary referral centre. Twenty-seven patients (9.7 ) satisfied the criteria for liver disease and their clinico-pathological features were assessed. The effect of UDCA on hepatobiliary symptoms and biochemical parameters was determined. RESULTS: The mean age at liver disease diagnosis was 23 years (range 8-47 years). Portal hypertension was present in 18 (67 ) patients. During a median follow-up of 7 years (range 1.5-15), variceal haemorrhage occurred in two patients and ascites in three (one spontaneously). Nine (33 ) patients died and five (19 ) underwent lung transplantation. There was no encephalopathy, liver transplantation or liver-related deaths. UDCA was taken by 22 patients and was associated with a significant improvement in hepatobiliary symptoms [11/22 (50 ) in the pre-UDCA period vs 1/22 (4 ) in the post-UDCA period; P=0.0003] and a significant reduction in aspartate aminotransferase (P=0.005); alanine aminotransferase (P

AB - BACKGROUND AND AIMS: The life expectancy of patients with cystic fibrosis (CF) has been increasing and the associated liver disease has emerged as a significant medical issue. Our aim was to describe the clinical features, course and effect of ursodeoxycholic acid (UDCA) on liver disease in an adult CF population. STUDY: From 1983 to 2005, 278 patients with CF were followed up at the Alfred Hospital, an adult tertiary referral centre. Twenty-seven patients (9.7 ) satisfied the criteria for liver disease and their clinico-pathological features were assessed. The effect of UDCA on hepatobiliary symptoms and biochemical parameters was determined. RESULTS: The mean age at liver disease diagnosis was 23 years (range 8-47 years). Portal hypertension was present in 18 (67 ) patients. During a median follow-up of 7 years (range 1.5-15), variceal haemorrhage occurred in two patients and ascites in three (one spontaneously). Nine (33 ) patients died and five (19 ) underwent lung transplantation. There was no encephalopathy, liver transplantation or liver-related deaths. UDCA was taken by 22 patients and was associated with a significant improvement in hepatobiliary symptoms [11/22 (50 ) in the pre-UDCA period vs 1/22 (4 ) in the post-UDCA period; P=0.0003] and a significant reduction in aspartate aminotransferase (P=0.005); alanine aminotransferase (P

UR - http://www.blackwell-synergy.com/doi/abs/10.1111/j.1478-3231.2007.01570.x

U2 - 10.1111/j.1478-3231.2007.01570.x

DO - 10.1111/j.1478-3231.2007.01570.x

M3 - Article

VL - 27

SP - 1402

EP - 1408

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 10

ER -